Importantly, increased levels of this inhibitory immune checkpoint on CD4+ T lymphocytes (but not CD8+) and NK cells correlated with shorter time to treatment in patients with CLL, thus suggesting an important role of BTLA dampening antitumor responses [89, 90]. The gene discussed is CD4; the disease is B-cell chronic lymphocytic leukemia.